Clinical trials: Spasm
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Muscle Spasm; Back Pain
Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial
The purpose of this study is to evaluate the efficacy of Eperisone HCl in the treatment of Acute Musculoskeletal spasm associated with Low-Back Pain.
- Trial name
- NCT00327730
- Testing
- Eperisone
- Where
- 4 sites in India
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Charcot-Marie-Tooth Disease
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
The COMMIT Study will assess the safety and effectiveness of FLX-787 in men and women with Charcot-Marie-Tooth disease (CMT) experiencing muscle cramps.
- Trial name
- COMMIT (NCT03254199)
- Testing
- FLX-787-ODT (orally disintegrating tablet)
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Flex Pharma, Inc.
Bronchospasm, Activity/Exercise Induced Bronchospasm
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test…
- Trial name
- NCT00118716
- Testing
- Fluticasone propionate/salmeterol, Fluticasone Propionate
- Where
- 50 sites in United States
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Abdominal Pain
(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis
The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated…
- Trial name
- NCT00932737
- Testing
- HBB 20 mg
- Where
- 19 sites in United States
- Volunteers
- 197 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit/Hyperactivity Disorder (ADHD)
The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder
The primary objective of this trial is to determine whether an oral administration of Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children suffering from ADHD.
- Trial name
- NCT00418184
- Testing
- Phosphatidylserine-Omega3, Colored cellulose tainted with fishy odor
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Enzymotec
Third Molar Extraction
Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil
Etoricoxib and cyclobenzaprine hydrochloride are active pharmaceutical ingredients (APIs) already registered in the country as mono-drugs.
- Trial name
- BENCOX (NCT05683574)
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Attention Deficit Disorder With Hyperactivity
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00556959
- Testing
- high dose clonidine HCl sustained release, low dose clonidine HCl sustained release
- Where
- 13 sites in United States
- Volunteers
- 236 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Back Pain
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
- Trial name
- NCT00817986
- Testing
- Arbaclofen placarbil, 20 mg, Arbaclofen placarbil, 30 mg, Arbaclofen placarbil, 40 mg
- Where
- 20 sites in United States
- Volunteers
- 161 people
- Sponsor
- XenoPort, Inc.
Muscle Spasm
Low Intensity Ultrasound Therapy for Upper Back Pain Relief
The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device for relief of pain associated with the trapezius muscle of the upper back over a 4-week period.
- Trial name
- NCT02135094
- Testing
- Active ultrasound therapy device
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ZetrOZ, Inc.
Post-cholecystectomy Gastrointestinal Spasms
Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm
Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg bis in die = twice a day (BID) and changes in quality of life in patients with…
- Trial name
- ODYSSEY (NCT02260154)
- Testing
- Mebeverine
- Where
- 21 sites in Russia
- Volunteers
- 220 people
- Sponsor
- Abbott
Nocturnal Leg Cramps
The Study of Efficacy and Safety of a 60-day Use of the Magnox Comfort Compared to the Placebo in Subjects With NLC
A randomized, multicenter, prospective, double-blind, placebo-controlled, clinical trial in the parallel groups to determine the efficacy and safety of a 60-day use of the dietary supplement Magnox Comfort compared to the placebo…
- Trial name
- NCT03807219
- Testing
- Magnox Comfort
- Where
- 7 sites in Ukraine
- Volunteers
- 216 people
- Sponsor
- Naveh Pharma LTD
Lower Back Pain
Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.
- Trial name
- NCT00671879
- Testing
- Carisoprodol SR 700 mg, Carisoprodol SR 500 mg
- Where
- 73 sites in United States
- Volunteers
- 830 people
- Sponsor
- Meda Pharmaceuticals
Asthma, Bronchospasm
Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction
This clinical study will evaluate and establish the protective effects of Amphastar's Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA), in preventing exercise-induced bronchoconstriction (EIB) in adolescent and adult…
- Trial name
- NCT00634829
- Testing
- albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma, Bronchospasm
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Conditions
- Asthma, Bronchospasm, Wheezing, Shortness of Breath
- Trial name
- NCT01188577
- Testing
- Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma, Bronchospasm
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of…
- Trial name
- NCT01174732
- Testing
- albuterol inhalation powder, albuterol inhalation aerosol
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
A study to assess bronchospasm potentially induced by HFO MDI as compared with HFA MDI in participants with well controlled or partially controlled asthma
- Trial name
- NCT05850494
- Testing
- HFA MDI, HFO MDI
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Refractory Infantile Spasms
A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients.
- Trial name
- NCT03976076
- Testing
- JBPOS0101
- Where
- 23 sites in United States, South Korea
- Volunteers
- 16 people
- Sponsor
- Bio-Pharm Solutions Co., Ltd.
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
- Trial name
- NCT03327402
- Testing
- SHP465
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire